TN1 |
Catalog No.GC34024 |
TN1은 강력한 태아 헤모글로빈(HbF) 유도제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 289479-94-3
Sample solution is provided at 25 µL, 10mM.
TN1 is a potent fetal hemoglobin (HbF) inducer.
A high-throughput screen of a large chemical library identifies a 2,6-diamino-substituted purine, TN1, which induces fetal hemoglobin (HbF) more potently than hydroxyurea in KU812 and K562 leukemia cell lines.TN1 increases HbF protein in both leukemic KU812 and K562 cells in a dose-dependent manner. At 100 nM concentration, Western blot analysis indicated that TN1 increased γ-globin expression (2.9- and 3.7-fold increase in KU812 cell and K562 cell, respectively) to higher levels than 50-100 μM HU (1.8- and 1.9-fold increase in KU812 cell and K562 cell, respectively), the first drug approved for the treatment of SCD. The EC50 value for TN1-mediated HbF induction is approximately three orders of magnitude lower than that of HU (HU: EC50=50-100 μM; TN1: EC50=100 nM). In addition, TN1 is more potent than a number of previously reported small-molecule HbF inducers including sodium butyrate and other histone deacetylase (HDAC) inhibitors. At the concentrations tested, TN1, as well as hemin and HU, increase γ-globin mRNA transcription (greater than fourfold), indicating that TN1 increases γ-globin levels at both the transcriptional and protein level. The time course of TN1-induced γ-globin mRNA and protein synthesis is measured and both increase after approximately 24 h of treatment. TN1 also induces β-globin mRNA in addition to γ-globin mRNA, similar to hydroxyurea[1].
[1]. Nam TG, et al. Identification and characterization of small-molecule inducers of fetal hemoglobin. ChemMedChem. 2011 May 2;6(5):777-80.
Cell experiment: | Representative images of PBMC culture in the presence of test compounds. PBMC are cultured in methylcellulose medium containing 0.9% methylcellulose, 30% fetal bovine serum (FBS), 2 mM glutamine, 1% deionized bovine serum albumin (BSA), 100 μM 2-mercaptoethanol, 10 ng recombinant human (rh) IL-3, and 3 U/mL rh erythropoietin (EPO) for 16 days in the presence of TN1 (30 nM) or HU (50 μM). HU treatment leads to smaller colonies and inhibition of maturation towards the erythrocyte lineage; b) Western blot of HbF with BFU-E colonies treated with DMSO, TN1 (30 nM), and HU (50 μM) after incubation for 18 days. β-actin is used as an internal control[1]. |
References: [1]. Nam TG, et al. Identification and characterization of small-molecule inducers of fetal hemoglobin. ChemMedChem. 2011 May 2;6(5):777-80. |
Cas No. | 289479-94-3 | SDF | |
Canonical SMILES | O=C(NC1=CC=CC(NC2=C3N=CN(CC)C3=NC(N[C@H]4CC[C@H](O)CC4)=N2)=C1)C#CC5=CC=C(C)C=C5 | ||
Formula | C29H31N7O2 | M.Wt | 509.6 |
Solubility | DMSO : 100 mg/mL (196.23 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.9623 mL | 9.8116 mL | 19.6232 mL |
5 mM | 0.3925 mL | 1.9623 mL | 3.9246 mL |
10 mM | 0.1962 mL | 0.9812 mL | 1.9623 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *